| Fibroblasts in the tumor microenvironment: shield or spear? T Alkasalias, L Moyano-Galceran, M Arsenian-Henriksson, K Lehti International journal of molecular sciences 19 (5), 1532, 2018 | 295 | 2018 |
| Inhibition of tumor cell proliferation and motility by fibroblasts is both contact and soluble factor dependent T Alkasalias, E Flaberg, V Kashuba, A Alexeyenko, T Pavlova, ... Proceedings of the National Academy of Sciences 111 (48), 17188-17193, 2014 | 113 | 2014 |
| A zebrafish model discovers a novel mechanism of stromal fibroblast-mediated cancer metastasis C Liu, Y Zhang, S Lim, K Hosaka, Y Yang, T Pavlova, T Alkasalias, ... Clinical Cancer Research 23 (16), 4769-4779, 2017 | 88 | 2017 |
| Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer L Moyano‐Galceran, EA Pietilä, SP Turunen, S Corvigno, E Hjerpe, ... EMBO molecular medicine 12 (4), e11177, 2020 | 55 | 2020 |
| RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivo T Alkasalias, A Alexeyenko, K Hennig, F Danielsson, RJ Lebbink, ... Proceedings of the National Academy of Sciences 114 (8), E1413-E1421, 2017 | 41 | 2017 |
| Prokineticin 1 is up‐regulated by insulin in decidualizing human endometrial stromal cells D Ujvari, I Jakson, C Oldmark, S Attarha, T Alkasalias, D Salamon, ... Journal of Cellular and Molecular Medicine 22 (1), 163-172, 2018 | 34 | 2018 |
| Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy A Salihi, MA Al-Naqshabandi, ZO Khudhur, Z Housein, HA Hama, ... Molecular Medicine Reports 26 (1), 233, 2022 | 18 | 2022 |
| Confrontation of fibroblasts with cancer cells in vitro: gene network analysis of transcriptome changes and differential capacity to inhibit tumor growth A Alexeyenko, T Alkasalias, T Pavlova, L Szekely, V Kashuba, ... Journal of Experimental & Clinical Cancer Research 34, 1-17, 2015 | 17 | 2015 |
| Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells T Alkasalias, J Zhang, H Madapura, B Dalarun, OB Reina, R Lewensohn, ... Cell Death Discovery 8 (1), 464, 2022 | 1 | 2022 |
| Tumor microenvironment: the paradoxical action of fibroblasts T Alkasalias PQDT-Global, 2018 | 1 | 2018 |
| Transcriptomic Profile of Breast Tissue of Premenopausal Women Following Treatment with Progesterone Receptor Modulator: Secondary Outcomes of a Randomized Controlled Trial D Utjés, NR Boggavarapu, MF Rasul, I Koberg, A Zulliger, ... International Journal of Molecular Sciences 25 (14), 7590, 2024 | | 2024 |
| Natural Killer Cell Dysfunction in Premenopausal BRCA1 Mutation Carriers: A Potential Mechanism for Ovarian Carcinogenesis S Haran, K Chindera, M Sabry, N Wilkinson, R Arora, A Zubiak, TE Bartlett, ... Cancers 16 (6), 1186, 2024 | | 2024 |
| Retinoblastoma vulnerability to combined de novo and salvage pyrimidine ribonucleotide synthesis pharmacologic blockage T Mollick, S Darekar, B Dalarun, F Plastino, J Zhang, AP Fernández, ... Heliyon 10 (1), 2024 | | 2024 |
| Transcriptomic profile of normal breast tissue post-mifepristone treatment: secondary outcomes of a randomized controlled trial D Utjes, N Boggavarapu, M Rasul, I Koberg, A Zulliger, S Srinivasan, ... medRxiv, 2024.03. 08.24303979, 2024 | | 2024 |
| Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells S Lain, T Alkasalias, J Zhang, H Madapura, B Dalaroun, OB Reina, ... | | 2022 |
| Correction: Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells T Alkasalias, J Zhang, H Madapura, B Dalarun, OB Reina, R Lewensohn, ... Cell Death Discovery 8, 2022 | | 2022 |
| Abstract GMM-041: OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH L Moyano-Galceran, SP Turunen, E Pietilä, T Alkasalias, S Corvigno, ... Clinical Cancer Research 25 (22_Supplement), GMM-041-GMM-041, 2019 | | 2019 |
| OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH L Moyano-Galceran, SP Turunen, E Pietila, T Alkasalias, S Corvigno, ... CLINICAL CANCER RESEARCH 25 (22), 104-104, 2019 | | 2019 |